Why Amgen Stock Sailed Through March Without a Scratch
While the broader markets took a historic beating during the month of March, shares of the biotech heavyweight Amgen (NASDAQ: AMGN) actually gained a modest 1.5% last month, according to data from S&P Global Market Intelligence.
To put the biotech's monthly performance into the proper context, the Dow Jones Industrial Average, the NASDAQ Composite Index, and the S&P 500 all lost more than 10% of their value in March. Amgen, in fact, was one of the only blue chip stocks to exit March in positive territory.
Image source: Getty Images.
Source Fool.com
